Skip to main content
Premium Trial:

Request an Annual Quote

Genset Announces Complete Sequencing of Two Bacteria Genomes

Premium

PARIS--Genset here announced that it has completely sequenced the genomes of two pathogens, Chlamydia pneumoniae, a possible agent for atherosclerosis lesions, and the Chlamydia trachomatis L2 strain. The company said it is applying for patents for both sequences and that it will license out the therapeutic, diagnostic, and vaccine applications of the genomic data to pharmaceutical companies.

The two bacteria infect a large number of eukaryotic cells and are responsible for a wide range of human diseases. "The determination and analysis of the complete sequence of this important pathogen is a clear demonstration of the power and quality of Genset's fully integrated genome analysis platform," claimed Pascal Brandys, Genset's chairman and CEO, about Chlamydia pneumoniae. He added that the sequencing work reinforces Genset's position in cardiovascular genomics research.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.